🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

p2a.co/phPNZN8 I just took action to save lives through cellular therapy, you can too! p2a.co/phPNZN8 #BeTheMatchAction #TransplantHope2020

VICC receives ‘exceptional’ score with renewal as an NCI-Designated Comprehensive Cancer Center news.vumc.org/2020/09/29/vic… via Vanderbilt Health

VICC leading first global study of MDS/MPN overlap syndrome news.vumc.org/2020/09/24/vic… via Vanderbilt Health

The MDS Foundation is honoring Vanderbilt's very own Dr. Stephen Brandt, Professor of Medicine, Div. of Hem/Onc, with a Nobility in MDS Award. Join us for the MDS Awareness Virtual Run/Walk in Nashville on Saturday, October 17th. MDS Foundation disq.us/t/3nzyf42

Excited to share a new paper from the lab identifying elevated IL1b responses in IDH mutated leukemia Leukemia Journal nature.com/articles/s4137… rdcu.be/cCuKp

This is the home of a classmate of one of my children. Please help if you can so we can restore the Season of Christmas for this family who lost their home. gofund.me/83c4c2a6

The future of research is happening HERE at SCRI. Scientific leaders, David R. Spigel, MD, FASCO, @BldCancerDoc from Sarah Cannon, and Dr. Andrew McKenzie lead attendees through the latest highlights in early and late phase research, blood cancer research, personalized medicine and beyond.

cell.com/immunity/fullt… Amazing times ... better understanding the immune system will improve options for cancer pts #beatingcancerisinourblood

A beautiful review on targeted therapies in AML! #leusm journals.lww.com/hemasphere/Ful…

Congress | #EHA2023 | Poster Gail Roboz, Weill Cornell Medicine Weill Cornell Leukemia summarizes a sub-analysis from the QUAZAR AML-001 trial. For pts with NPM1 mutated AML at diagnosis, serial NPM1mut monitoring is feasible. Post-IC MRD negativity was associated with improved outcomes. #leusm

CONGRESS|#EHA2023 Richard Schlenk Heidelberg University presents the results from the QuANTUM-First trial evaluating allo-HCT in 1st complete remission + quizartinib. Pts on Quiz who underwent allo-HCT in CR1 had longer OS than pts on placebo #AMLsm #leukemia #leusm #medicalcongress

#ASCO23 | Poster Kendall Diebold UAB discussed findings that 3-day condensed schedule of cytarabine gives earlier hematopoetic recovery and is as safe as standard 5-day schedule. #leusm

medpagetoday.com/opinion/second…

FDA approves quizartinib (Vanflyta, Daiichi Sankyo, Inc.) with standard cytarabine and anthracycline induction and cytarabine consolidation for newly diagnosed acute myeloid leukemia (#AML). Drug label: bit.ly/3OlV3Rr

Wonderful presentation by Vivek Subbiah, MD on Precision Medicine Beyond Trauma Foundation 2023 Summit on Hematologic Cancers

Enjoying my colleague Jeremy Pantin educate me about PNH therapeutic options during OncLive.com State of the Science Summit in Nashville,TN

Exciting results from Syros looking to create an optimistic outlook for AML patients businesswire.com/news/home/2023…

She was a new mother living with cancer. Now, she looks to help other mothers newschannel5.com/news/she-was-a… #sarahcannon@tristarcentennial

#DYK we fund initiatives to accelerate the development of innovative #BloodCancer treatments to change the standard of care in blood cancer? Kura Oncology is one of the many biotech companies we support, and they just presented findings from a trial assessing a menin inhibitor

That’s a wrap for a fantastic menin inhibitor session at #ASH24 featuring revumenib, enzomenib, Bleximenib, ziftomenib & combinations with SOC therapies . Wonderful informative presentations by Joshua Zeidner MD , Dr. Aldoss, Amer Zeidan MBBS,MHS ‏عامر زيدان Ghayas Issa & Emma Seattle. See my detailed